These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 28189365)

  • 21. Strategies to improve bioavailability of omega-3 fatty acids from ethyl ester concentrates.
    Maki KC; Dicklin MR
    Curr Opin Clin Nutr Metab Care; 2019 Mar; 22(2):116-123. PubMed ID: 30550388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel liquid chromatography/tandem mass spectrometry (LC-MS/MS) based bioanalytical method for quantification of ethyl esters of Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) and its application in pharmacokinetic study.
    Viswanathan S; Verma PRP; Ganesan M; Manivannan J
    J Pharm Biomed Anal; 2017 Jul; 141():250-261. PubMed ID: 28463780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Food on the Pharmacokinetics of Omega-3-Carboxylic Acids in Healthy Japanese Male Subjects: A Phase I, Randomized, Open-label, Three-period, Crossover Trial.
    Shimada H; Nilsson C; Noda Y; Kim H; Lundström T; Yajima T
    J Atheroscler Thromb; 2017 Sep; 24(9):980-987. PubMed ID: 28344197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparative bioavailability of eicosapentaenoic acid and docasahexaenoic acid from triglycerides, free fatty acids and ethyl esters in volunteers].
    Beckermann B; Beneke M; Seitz I
    Arzneimittelforschung; 1990 Jun; 40(6):700-4. PubMed ID: 2144420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic Bioavailability and Dose Proportionality of Omega-3 Administered in Free Fatty Acid Form Compared With Ethyl Ester Form: Results of a Phase 1 Study in Healthy Volunteers.
    Offman E; Davidson M; Abu-Rashid M; Chai P; Nilsson C
    Eur J Drug Metab Pharmacokinet; 2017 Oct; 42(5):815-825. PubMed ID: 28116646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review.
    Oscarsson J; Hurt-Camejo E
    Lipids Health Dis; 2017 Aug; 16(1):149. PubMed ID: 28797250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized double-blind (ORD) study.
    Tatsuno I; Saito Y; Kudou K; Ootake J
    J Clin Lipidol; 2013; 7(3):199-207. PubMed ID: 23725919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel self-micro-emulsifying delivery system (SMEDS) formulation significantly improves the fasting absorption of EPA and DHA from a single dose of an omega-3 ethyl ester concentrate.
    Qin Y; Nyheim H; Haram EM; Moritz JM; Hustvedt SO
    Lipids Health Dis; 2017 Oct; 16(1):204. PubMed ID: 29037249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioavailability of marine n-3 fatty acid formulations.
    Dyerberg J; Madsen P; Møller JM; Aardestrup I; Schmidt EB
    Prostaglandins Leukot Essent Fatty Acids; 2010 Sep; 83(3):137-41. PubMed ID: 20638827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study).
    Braeckman RA; Manku MS; Bays HE; Stirtan WG; Soni PN
    Prostaglandins Leukot Essent Fatty Acids; 2013 Sep; 89(4):195-201. PubMed ID: 23992935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk stratification by the "EPA+DHA level" and the "EPA/AA ratio" focus on anti-inflammatory and antiarrhythmogenic effects of long-chain omega-3 fatty acids.
    Rupp H; Wagner D; Rupp T; Schulte LM; Maisch B
    Herz; 2004 Nov; 29(7):673-85. PubMed ID: 15580322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
    McKenney JM; Sica D
    Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The free fractions of circulating docosahexaenoic acid and eicosapentenoic acid as optimal end-point of measure in bioavailability studies on n-3 fatty acids.
    Scarsi C; Levesque A; Lisi L; Navarra P
    Prostaglandins Leukot Essent Fatty Acids; 2015 May; 96():11-6. PubMed ID: 25559240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dietary sesamin and docosahexaenoic and eicosapentaenoic acids synergistically increase the gene expression of enzymes involved in hepatic peroxisomal fatty acid oxidation in rats.
    Arachchige PG; Takahashi Y; Ide T
    Metabolism; 2006 Mar; 55(3):381-90. PubMed ID: 16483883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Single-dose, Comparative Bioavailability Study of a Formulation containing OM3 as Phospholipid and Free Fatty Acid to an Ethyl Ester Formulation in the Fasting and Fed States.
    Lapointe JF; Harvey L; Aziz S; Jordan H; Hegele RA; Lemieux P
    Clin Ther; 2019 Mar; 41(3):426-444. PubMed ID: 30799231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relative bioavailability and pharmacokinetics of two oral formulations of docosahexaenoic acid/eicosapentaenoic acid after multiple-dose administration in healthy volunteers.
    Rusca A; Di Stefano AF; Doig MV; Scarsi C; Perucca E
    Eur J Clin Pharmacol; 2009 May; 65(5):503-10. PubMed ID: 19148629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study.
    Tatsuno I; Saito Y; Kudou K; Ootake J
    J Clin Lipidol; 2013; 7(6):615-25. PubMed ID: 24314359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ω-3 carboxylic acids for hypertriglyceridemia.
    Roth EM
    Expert Opin Pharmacother; 2015 Jan; 16(1):123-33. PubMed ID: 25480558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing the Impact of Prescription Omega-3 Fatty Acid Products on Low-Density Lipoprotein Cholesterol.
    Sharp RP; Gales BJ; Sirajuddin R
    Am J Cardiovasc Drugs; 2018 Apr; 18(2):83-92. PubMed ID: 29080985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incorporation and washout of orally administered n-3 fatty acid ethyl esters in different plasma lipid fractions.
    Zuijdgeest-van Leeuwen SD; Dagnelie PC; Rietveld T; van den Berg JW; Wilson JH
    Br J Nutr; 1999 Dec; 82(6):481-8. PubMed ID: 10690163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.